Opinion statement Relapse is still a common scenario in acute myeloid leukemia (AML)
treatment and occurs in 40–50% of younger and the great majority of elderly patients. The …

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

Background Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal
prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax …

Individuals with acute myeloid leukemia (AML) harboring an internal tandem duplication
(ITD) in the gene encoding Fms-related tyrosine kinase 3 (FLT3) who relapse after …

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative
treatment for acute myeloid leukemia (AML). However, most patients experience relapse …

Allogeneic hematopoietic stem cell transplantation (allo-SCT) remains the therapeutic
method with the most potent anti-leukemic activity mediated by the graft versus leukemia …

Relapse is the main cause of treatment failure after allogeneic stem cell transplant (alloSCT)
in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Injectable …

Despite therapeutic progress in acute myeloid leukemia (AML), relapse post-allogeneic
hematopoietic stem cell transplantation (allo-HSCT) remains a major challenge. Here, we …

Acute myeloid leukemia (AML) is a phenotypically and prognostically heterogeneous
hematopoietic stem cell disease that may be cured in eligible patients with intensive …

Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic cell transplantation
(allo-HCT) has a dismal prognosis. We found that T cells of patients relapsing with AML after …